Literature DB >> 33482846

The serum levels of circulating matrix metalloproteinase MMP-9, MMP-2/TIMP-2 complex and TIMP-1 do not change significantly during normal pregnancy: a pilot study.

Ritva Nissi1, Markku Santala2, Anne Talvensaari-Mattila2.   

Abstract

OBJECTIVE: Matrix metalloproteinases (MMPs) are important regulators of vascular and uterine remodeling. They exhibit proteolytic activity implicating the efficiency of trophoblast invasion to the uterine wall involving marked hemodynamic and uterine changes. In this pilot study sera of 13 women with normal pregnancy was analyzed to evaluate the usage of MMPs as diagnostic tool. The concentrations of circulating MMP-9, MMP-2/TIMP-2 complex and TIMP-1 in different time points during normal pregnancy has not been studied. The serum levels of MMP-9, TIMP-1, TIMP-2 and MMP-2/TIMP-2 complex were determined by enzyme-linked immunosorbent assay (ELISA). Using the same method, we have shown that serum MMPs are elevated in spontaneous early pregnancy failure as compared to normal pregnancy.
RESULTS: The serum levels of MMP-9 and TIMP-1 were stable throughout pregnancy. The level of MMP-2/TIMP-2 complex was slightly increased after week 15 without statistical significance. For our best knowledge, this is a first study of the serum levels of MMP-9, MMP-2/TIMP-2 and TIMP-1 on different time points during normal pregnancy. Further measurements with the correlation to the outcome of the pregnancy are needed.

Entities:  

Keywords:  Matrix metalloproteinases (MMPs); Pregnancy; Tissue inhibitors of matrix metalloproteinases (TIMPs)

Mesh:

Substances:

Year:  2021        PMID: 33482846      PMCID: PMC7821532          DOI: 10.1186/s13104-021-05442-w

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


  8 in total

1.  Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls.

Authors:  Nemanja Stojanovic; Krzysztof Lewandowski; Ireneusz Salata; Malgorzata Bienkiewicz; Susan Tuck; Gordana Prelevic; Martin Press
Journal:  Gynecol Endocrinol       Date:  2010-03       Impact factor: 2.260

Review 2.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

3.  Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

Authors:  S Ylisirniö; M Höyhtyä; T Turpeenniemi-Hujanen
Journal:  Anticancer Res       Date:  2000 Mar-Apr       Impact factor: 2.480

4.  Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones.

Authors:  Zongzhi Yin; Alaa A Sada; Ossama M Reslan; Neha Narula; Raouf A Khalil
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-04-10       Impact factor: 4.310

5.  Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction.

Authors:  Vicki Plaks; Julie Rinkenberger; Joanne Dai; Margaret Flannery; Malin Sund; Keizo Kanasaki; Wei Ni; Raghu Kalluri; Zena Werb
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

6.  Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor.

Authors:  Inge Tency; Hans Verstraelen; Ivo Kroes; Gabriële Holtappels; Bruno Verhasselt; Mario Vaneechoutte; Rita Verhelst; Marleen Temmerman
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

7.  Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia.

Authors:  Marzena Laskowska
Journal:  Biomed Res Int       Date:  2017-07-17       Impact factor: 3.411

8.  Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.

Authors:  Ritva Nissi; Anne Talvensaari-Mattila; Vesa Kotila; Maarit Niinimäki; Ilkka Järvelä; Taina Turpeenniemi-Hujanen
Journal:  Reprod Biol Endocrinol       Date:  2013-01-15       Impact factor: 5.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.